US-based Zydus Pharmaceuticals, a subsidiary of Zydus Cadila, has received final approval from the US Food and Drug Administration (USFDA) to market Lamotrigine tablet, in the strengths of 2 mg, 5 mg and 25 mg.
Lamotrigine is used for the treatment of partial seizures and for long-term management of bipolar disorder.Cadila Healthcare is the flagship company of the Zydus Cadila group. The group is engaged in pharmaceuticals (human formulations, veterinary formulations and bulk drugs), diagnostics, herbal products, skin care products and OTC products.
Shares of the company closed down Rs 5.2, or 2.14%, at Rs 238. The total volume of shares traded at the BSE was 558 (Friday).